Evidence map›Paper›PMID 41752436›Full record

ArticleMolecules (Basel, Switzerland)2026

Abietane-Type Diterpenoids from the Resin of

Cheng-Tian Tao, Jing Liu, Li Wan, Yong-Xian Cheng

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Cheng-Tian TaoSchool of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Jing LiuSchool of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Li WanSchool of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.ORCID 0000-0003-2556-1827
Yong-Xian ChengSchool of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.ORCID 0000-0003-1643-9598

Funding

Shenzhen Fundamental Research Program No. JCYJ20200109114003921Shenzhen Fundamental Research Program NO. JCYJ20210324120213038
6 · The paper itself

Abstract

Chronic kidney disease (CKD) has emerged as a pressing global public health concern, making the identification of renal fibrosis inhibitors a key research focus. In this study, seven undescribed abietane-type diterpenoids, pinusyunins A-G (

Indexed as

AbietanesAntifibrotic AgentsKidneyKidney DiseasesPinusResins, PlantActinsAnimalsCell LineFibronectinsFibrosisRatsSignal TransductionSmad3 ProteinTransforming Growth Factor beta1AbietanesActinsAntifibrotic AgentsFibronectinsResins, PlantSmad3 ProteinTransforming Growth Factor beta1abietane-type diterpenoidsanti-renal fibrosisPinus yunnanensisTGF-β/Smad signaling pathway

Identifiers

PMID41752436
PMCPMC12943051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.